Answers are grounded in this paper and cite their sources.
Although several considerations have been raised suggesting a beneficial effect of N-acetyl cysteine (NAC) for the treatment of severe acute respiratory syndrome coronavirus 2 infection, there is currently no clinical evidence that NAC truly prevents coronavirus disease 2019 (COVID-19), reduces the severity of the disease, or improves the outcome. Appropriately designed clinical trials are warranted to prove or disprove a therapeutic effect of NAC for COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Finsterer et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: